NovoCure Ltd., a global oncology company specializing in Tumor Treating Fields (TTFields) technology, reported a net revenue of $655.4 million for the fiscal year ending December 31, 2025, marking an 8% increase from $605.2 million in 2024. The growth was primarily driven by increased sales in France, Germany, and other international markets, despite a slight decline in U.S. revenues due to reduced one-time benefits from prior claims. The company also reported a net loss of $136.2 million for 2025, an improvement from a loss of $168.6 million in the previous year.
In terms of operational metrics, NovoCure's active patient count rose to 4,620 by the end of 2025, up from 4,077 in 2024. The company reported 4,183 prescriptions for its Optune devices in the U.S. and 2,852 in international markets, indicating a steady demand for its products. The company’s gross margin decreased slightly to 75% from 77% in 2024, attributed to higher costs associated with tariffs and array production.
Strategically, NovoCure has been focused on expanding its product offerings and market presence. The company is actively pursuing regulatory approvals for its devices in new indications, including brain metastases from non-small cell lung cancer (NSCLC). In December 2025, NovoCure submitted a Premarket Approval (PMA) application for its device under the proposed brand name Optune Mya, which is currently under review by the FDA. Additionally, the company has established a collaboration with Zai Lab to commercialize its products in Greater China, which is expected to enhance its market reach.
The company’s workforce increased to 1,605 employees as of December 31, 2025, up from 1,488 the previous year, reflecting its commitment to scaling operations in line with growth objectives. NovoCure's financial position remains robust, with $93.5 million in cash and cash equivalents and $354.1 million in short-term investments as of the end of 2025. However, the company anticipates continued operational expenses as it invests in research and development, sales, and marketing to support its growth trajectory.
Looking ahead, NovoCure aims to leverage its proprietary TTFields technology to drive further adoption of its products while navigating the complexities of regulatory approvals and market competition. The company remains focused on enhancing its operational efficiencies and expanding its product pipeline to address unmet medical needs in oncology.
About NovoCure Ltd
NovoCure Limited is a global oncology company specializing in Tumor Treating Fields (TTFields) technology, which uses electric fields to disrupt cancer cell division. Its core products, Optune Gio and Optune Lua, are medical devices approved for treating glioblastoma, non-small cell lung cancer, and mesothelioma. The company markets its therapies worldwide, emphasizing clinical research, regulatory compliance, and innovative device development to extend survival and improve quality of life for cancer patients.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.